RMI Partners
RMI Partners is VC firm focused on breakthrough developments of pharmaceutical products and technologies based in the U.S. and Russia.
Business Model:
Revenue: $5.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed RMI Partners Information
Geographic Data
Address: 29, 1-st Brestskaya Street
City: Moscow
State: moscow (city)
Zip: 125047
Country: RU
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
RMI Partners is a venture company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas. RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2014 | Atea Pharmaceuticals | Series A | 20M |
| 7/2014 | Epic Sciences | Series C | 0 |
| 4/2017 | Epic Sciences | Series D | 0 |
| 4/2017 | NovaDigm Therapeutics | Convertible Note | 0 |
| 1/2018 | Celtaxsys | Series E | - |
| 6/2016 | Clearside Biomedical | Funding Round | 0 |
| 10/2013 | NovaDigm Therapeutics | Series B | 7M |
| 6/2015 | Celtaxsys | Series D | 0 |
| 8/2013 | Adastra Pharmaceuticals | Series B | 9.4M |
| 6/2014 | Tobira Therapeutics | Debt Financing | 15M |
| 8/2014 | ALDEA Pharmaceuticals | Series B | 24M |
| 7/2013 | ReVision Optics | Series E | 55M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 12/2012 | Evofem Biosciences | Series C | 20.6M |
| 10/2013 | NovaDigm Therapeutics | Venture Round | 7M |
| 11/2014 | NovaDigm Therapeutics | Series B | 7M |
| 8/2015 | Adastra Pharmaceuticals | Series C | 0 |
| 7/2012 | Ocunexus Therapeutics | Series B | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 7/2015 | Adastra Pharmaceuticals | Convertible Note | 0 |
| 4/2014 | Transcend Medical | Series C | 0 |
| 12/2012 | Regado Biosciences | Series E | 0 |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 9/2014 | Clearside Biomedical | Series B | 16M |
| 1/2015 | Binx Health | Series C | 0 |
| 1/2017 | Binx Health | Series D | 0 |
| 4/2013 | ReVision Optics | Equity | 15M |
| 1/2015 | Transcend Medical | Venture Round | 7.2M |
| 12/2012 | Marinus Pharmaceuticals | Venture Round | 11.4M |
| 4/2014 | Adastra Pharmaceuticals | Series B | 3M |
| 1/2018 | Celtaxsys | Series E | - |
| 4/2017 | NovaDigm Therapeutics | Convertible Note | 0 |
| 4/2017 | Epic Sciences | Series D | 0 |
| 1/2017 | Binx Health | Series D | 0 |
| 6/2016 | Clearside Biomedical | Funding Round | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 8/2015 | Adastra Pharmaceuticals | Series C | 0 |
| 7/2015 | Adastra Pharmaceuticals | Convertible Note | 0 |
| 6/2015 | Celtaxsys | Series D | 0 |
| 1/2015 | Binx Health | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
